ACADIA PHARMACEUTICALS INC — Director's Dealing 2013

May 3, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2013-05-01

Reporting Person: Hacksell Uli (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-05-01	Common Stock	M	19551	$1.08	Acquired	19551	Direct
2013-05-01	Common Stock	G	19551	—	Disposed	0	Direct
2013-05-01	Common Stock	G	19551	—	Acquired	128600	Indirect
2013-05-01	Common Stock	S	19551	$12.7113	Disposed	109049	Indirect
2013-05-02	Common Stock	M	20449	$1.08	Acquired	20449	Direct
2013-05-02	Common Stock	G	20449	—	Disposed	0	Direct
2013-05-02	Common Stock	G	20449	—	Acquired	129498	Indirect
2013-05-02	Common Stock	S	20449	$12.3427	Disposed	109049	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-05-01	Stock Option (right to buy)	$1.08	M	19551	Disposed	2013-09-07	Common Stock (19551)	Direct
2013-05-02	Stock Option (right to buy)	$1.08	M	20449	Disposed	2013-09-07	Common Stock (20449)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2012.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.85 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.30 to $12.39 per share, inclusive.

F4: Immediately.